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Background: As sharing and secondary research use of biospecimens increases, IRBs and researchers face the
challenge of protecting and respecting donors without comprehensive regulations addressing the human subject
protection issues posed by biobanking. Variation in IRB biobanking policies about these issues has not been well
documented.
Methods: This paper reports on data from a survey of IRB Administrative Directors from 60 institutions affiliated
with the Clinical and Translation Science Awards (CTSAs) about their policies and practices regarding secondary use
and sharing of biospecimens. Specifically, IRB ADs were asked about consent for future use of biospecimens,
assignment of risk for studies using biobanked specimens, and sharing of biospecimens/data.
Results: Our data indicate that IRBs take varying approaches to protocol review, risk assessment, and data sharing,
especially when specimens are not anonymized.
Conclusion: Unclear or divergent policies regarding biospecimen research among IRBs may constitute a barrier to
advancing genetic studies and to inter-institutional collaboration, given different institutional requirements for
human subjects protections.
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In recent years, questions about how to apply human
subjects protections to biobanking-related research have
challenged institutional review boards (IRBs) [1-4]. These
include: what consent approaches are appropriate for col-
lecting, storing, and using research participants’ biospe-
cimens and their associated data; whether and how
language in original consent forms should be considered
when conducting secondary studies using stored biospeci-
mens; what level of risk (no more than minimal or greater
than minimal) should be assigned to studies using stored
biospecimens; and what requirements should be imposed
for sharing biospecimens with internal and external re-
searchers [4-7]? Regulations governing research involving
human subjects do not explicitly address the unique hu-
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question are collected prospectively or previously stored.
Furthermore, inconsistent guidance from government
agencies, research organizations, and professional societies
may make it difficult for researchers and IRBs to deter-
mine how biospecimens/data should be collected, stored,
and used in ways that protect the rights and welfare of
biospecimen donors while advancing genetic and other
biomedical research [6].
The challenges IRBs face with regard to human sub-
jects protections for biobanking-related research may be
magnified when researchers at one institution seek to
share biospecimens with external researchers or to con-
duct research with biospecimens/data they obtain from
other institutions [8]. Variations across IRBs in policies
and procedures regarding human subjects protections
for biobanking-related research add to the complexity of
cross-institutional collaboration and may hinder certain
kinds of potentially beneficial research endeavors [9].
Little is known about the degree of variety among IRBntral. This is an Open Access article distributed under the terms of the Creative
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search, particularly genetic research and research involv-
ing inter-institutional collaboration or data sharing [7].
The present survey of IRB Administrative Directors
(ADs) represents one aim of a larger NIH-funded study
designed to better understand the range and variation of
IRB policies and practices regarding human subject pro-
tections in the context of the collection, storage and use
of biospecimens and associated data.
The purposes of the larger study are to 1) describe
the usual practices and attitudes of stakeholder groups
at Clinical and Translational Science Award (CTSA)
institutions (including IRB administrators) about spe-
cific policy options in order to address and understand
potential barriers to collaborative research; 2) under-
stand how institutional policies controlling the cre-
ation and use of biobanks are developed; and 3)
analyze, through an interdisciplinary process, the eth-
ical and regulatory issues that frame policies on in-
formed consent and sharing biospecimens/data across
institutions, and 4) develop a set of policy/practice
recommendations.
Funded by the National Center for Advancing Transla-
tional Sciences, a part of the National Institutes of
Health (NIH), the CTSA program represents a core in-
frastructure for publicly funded translational research in
the United States [10]. It is a key example of the growing
trend toward promoting collaborative research within
and across sites in order to facilitate interventions from
the laboratory bench to the bedside. This national consor-
tium exemplifies the growing importance of collaborative
research, in which member institutions are expected to
transform clinical and translational research and cooper-
ate within and across sites. [10] In this report, we describe
key human subjects protection issues that IRBs at CTSA
institutions confront as they review biobanking-related re-
search protocols.Methods
To characterize IRB practices, we surveyed IRB Admin-
istrative Directors (ADs) from every CTSA program
established as of 2012 (N = 60). These are the individuals
who supervise and oversee IRB operations, are most
likely responsible for promulgating IRB policies and pro-
cedures, and typically are most knowledgeable about
usual IRB practices at their institutions. We recruited
IRB ADs from all 60 CTSA sites (as of 2012 when sur-
veys were conducted) as the target sample. For CTSAs
consisting of multiple institutions represented by numer-
ous IRBs, we surveyed the AD of the IRB at the institu-
tion within that CTSA which received the most NIH
funding (according to the NIH Research Portfolio On-
line Reporting Tool (RePORT) [11].Survey design
We sought to learn how research institutions in the
CTSA consortium approach the protection of research
participants in biobanking-related research. We focused
on institutions’ IRB policies and usual practices for
obtaining consent for research involving biobanking, and
on sharing biospecimens/data across academic institu-
tions. Based on the expertise of the research team and a
review of the literature, we developed a preliminary 33-
item survey that we pretested with 6 local IRB represen-
tatives to assess ease of survey administration and face
validity. We then developed a final survey comprising 37
questions, primarily using a five-point Likert answer
scale (Additional file 1).
Throughout the survey we used the term “Biospecimens
and Data” to reflect that in the context of specimen re-
search, the samples themselves are valuable insofar as
they are associated with or help to generate data.
Through this survey, we wanted to capture Administra-
tive Directors’ views on practices and policies surround-
ing these as one concept, to better reflect the context of
specimen research. We will therefore use the term
“biospecimen” or “specimen” throughout the rest of this
paper to represent both the sample itself, data associ-
ated or linked with that sample, and or data generated
from using a sample.
Survey sample and administration of survey
After identifying eligible IRB ADs at each CTSA insti-
tution in our target sample (using institutional web-
sites and personal contacts at some of the institutions),
a member of the research team called each potential
respondent to verify his/her position at the institution
and to confirm all contact information. Study staff
followed up with a telephone call to explain the pro-
ject, determine the AD’s interest in participating in the
survey, and schedule a time to administer the survey
via phone. We sent an email to confirm the survey ses-
sion time, and attached a copy of the survey and an in-
formation sheet about the study in advance of the
scheduled survey.
Surveys were administered by telephone, and took
place between June and August of 2012. Verbal con-
sent was obtained from each participant prior to be-
ginning data collection. On average, surveys lasted
approximately 45 minutes. In addition to the investiga-
tor administering the survey, two additional project
staff members were present during the phone calls in
order to ensure accurate capture of participants’ re-
sponses. This project was reviewed and approved by
the Institutional Review Board of University Hospitals
in Cleveland, OH. The IRB waived the requirement for
documentation of informed consent for participation
in this survey.
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Survey data were managed using Research Electronic
Data Capture Application (REDCap) software, hosted at
Case Western Reserve University (CWRU). REDCap is a
secure, web-based application designed to support data
capture and analysis for research studies [12]. Survey
data were de-identified and entered into the REDCap
database. All descriptive analyses were conducted using
REDCap software.
Results
We surveyed 51 IRB ADs, representing an 85% response
rate. Respondents’ length of experience in their positions
ranged from less than 1 year to 22 years (median 8.8
years). Most (57%) of the IRBs represented by the ADs
reviewed more than 100 new protocols involving genetic
research each year. Seventy-five percent of the institu-
tions’ IRBs had received the optional IRB accreditation
by the Association for the Accreditation of Human Re-
search Protection Programs (AAHRPP). The following
results sections focus on two primary areas of inquiry: 1)
general IRB practices regarding risk and review require-
ments for studies using previously stored biospecimens
(and associated data) within their institutions, and 2)
IRB practices regarding the sharing of biospecimens with
researchers at other (“outside”) institutions.
IRB practices regarding risk and review requirements for
studies using stored biospecimens
Level of risk attributed to research using biobanked
specimens/data
We asked respondents, “What level of risk [their] IRBs
would typically assign a study using stored specimens
and data?” Respondents were then asked to rate the level
of risk their IRBs would typically assign to a proposed
study using stored specimens with differing degrees of
identifiers (Table 1). We defined anonymized biospeci-
mens as having no identifiers or codes linked to iden-
tifying information about the donors and coded/de-
identified biospecimens as being linked to identifying in-
formation about the donors, without the researcher hav-
ing access to the key that links the code to identifying
information.
For anonymized and de-identified specimens, there
was general agreement across institutions about theTable 1 Level of risk associated with the use of stored
biospecimens
No greater than






Anonymized 50 (98) 0 (0) 1 (2)
Coded 44 (86) 5 (10) 2 (4)
Identified 23 (45) 16 (31) 12 (24)assignment of risk. Ninety-eight percent of respon-
dents said their IRBs consider studies using anon-
ymized biospecimens to be no greater than minimal
risk. Similarly, 86% of respondents said that studies
using coded specimens also would be considered no
greater than minimal risk. However, when attributing
risk to the proposed use of identified specimens and
data, responses were more heterogeneous. While 45%
of respondents believed their IRBs would classify these
kinds of studies as “no greater than minimal risk,” 31%
felt their IRBs would assign the research as “greater
than minimal risk,” and 23% of IRB ADs were either
unsure what risk their IRBs would assign or felt that it
would depend on the study and specific details regard-
ing the proposed research.
Practices regarding review of protocols using biobanked
biospecimens
We then asked the ADs “whether [their] IRBs would
typically require a researcher to submit information
about their study (using biospecimens) to determine if
the study is exempt from the oversight requirements of
the Common Rule or require further IRB review.” While
there was some consistency in answers across ADs, their
IRBs’ approaches depended on the identifiability of the
samples in question. For anonymized data, a majority
(61%) of ADs said their IRBs would usually or always re-
quire a researcher to submit his or her study for an ini-
tial review, while 39% said that their IRBs would never,
rarely, or sometimes require this practice. When speci-
mens are coded/de-identified, 82% of ADs said their
IRBs would usually or always require researchers to sub-
mit study information, and 100% of ADs reported that
when studies utilize identifiable specimens their IRB
would require the researchers to submit information to
the IRB about their studies.
IRB practices for reviewing original consent language
Respondents also were asked if their IRBs would “typic-
ally review the original consent language” from the stud-
ies for which participants’ data and specimens were
collected, in order to assess whether a new use would
fall within the scope of the original consent form.
Thirty-four percent of respondents reported that their
IRBs would review the original consent form language if
the new study proposed to use only anonymized speci-
mens. This number increased to 61% for coded/de-iden-
tified specimens and to 84% for identifiable specimens.
There also appear to be differences in what IRBs look
for when reviewing a consent form to determine
whether a proposed new study involving banked speci-
mens falls within the scope of the uses described in the
original consent form authorizing their collection or
storage for research. Thirty percent of respondents said
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study is “consistent” with the original uses described in
the consent form, whereas 69% said their IRBs would
want to know that the study is “not inconsistent” with
uses described. This distinction may result in material
differences for researchers. The approach of seeking
consistency requires congruence, which is more limiting.
The approach of verifying a lack of inconsistency can re-
sult in a broader scope of use than the original approv-
ing IRB and research participants may have imagined.
Acceptability of research practices for studies that fall
outside the original scope of consent
Respondents were asked about “the acceptability of dif-
ferent approaches to resolve issues related to stored
sample use, when a proposed study is determined to fall
outside the original scope of consent” (Table 2). A ma-
jority (78%) of ADs reported that their IRBs would either
encourage or require seeking new consent from biospe-
cimen donors/research participants. However, there were
more diverse responses with respect to the option to
anonymize the data at the time of the new study. Thirty-
one percent of IRBs prohibit this option, while 14% dis-
courage it, 24% permit it, 17% encourage it and 14% re-
quire it. Nearly 37% of IRBs prohibit or discourage a
request for a waiver of informed consent whereas almost
24% encourage or require this option when faced with a
request for a new use outside the scope of the original
consent used for specimen collection.
Biospecimen sharing with “outside” institutions
With regard to sharing biospecimens/data with re-
searchers outside of their own institutions, we asked the
ADs to, “imagine that a researcher at your institution
has a collection of biospecimens/data that he would like
to share with a researcher outside your institution.” Re-
spondents were then asked whether their institutions’
IRBs would require either 1) submission of information
about the proposed study and/or 2) documentation of
the outside institution’s IRB authorization for theTable 2 Acceptability of data management options for























5 (10) 14 (28) 20 (39) 8 (16) 4 (8)proposed study. Responses varied depending on the
identifiability of the biospecimens and whether the ori-
ginal investigator who collected the specimens would be
involved in the proposed study.IRB requirements for biospecimen/data sharing without
original researcher involvement (non-collaborative
proposal)
When a researcher wishes only to provide biospecimens
to another researcher, and will not be involved in the
new study, 29% of IRBs would require any information
about the proposed study and 24% would require docu-
mentation from the external (receiving) researcher’s IRB
when the biospecimens are anonymized (Table 3). When
biospecimens are coded/de-identified, 43% of IRBs typic-
ally would require an information review and 65% would
require documentation of the outside institution’s IRB
authorization. If the specimens were identified, approxi-
mately 58% of IRBs would require both information about
the proposed study and evidence of IRB authorization at
the receiving investigator’s institution.IRB requirements for biospecimen sharing with original
researcher involvement (collaborative proposal)
When the researcher who collected the biospecimens
will collaborate with researchers at another institution to
conduct a new study using the existing biospecimens,
even when those specimens have been anonymized, 55%
of the IRBs would require documentation of IRB
authorization by the collaborators’ external site(s) and
78% would require submission of information about
the new study (Table 3). When the biospecimens are
coded/de-identified, 94% would require information
about the study and 71% would want to receive the
outside institution’s IRB authorization. Lastly, when
biospecimens are identifiable, 100% of institutions would
require study information and 75% would require IRB
documentation.IRB requirements for proposed projects using biospecimens
from outside institutions
Respondents were asked to, “Imagine that a researcher
at your institution proposes a study that would involve
only biospecimens that she would obtain from a source
outside your institution.” Respondents were then asked
whether their IRBs would require a review of the original
consent form before a researcher at their institutions
could use biospecimens provided by another institution.
Thirty-nine percent said their IRBs always or usually re-
view the original consent form when biospecimens are
coded/de-identified, whereas 65% said their IRBs would
always require review when biospecimens are identifiable.
Table 3 IRB requirements when the original researcher will or will NOT be involved in proposed study using previously
collected biospecimens
Original researcher NOT involved Original researcher involved
Level of Identifiability Yes/Usually n (%) Yes/Usually n (%)
Anonymized Require submission of information about the new study 15 (29) 40 (78)
Require submission of documentation of review from
external researcher’s IRB
12 (24) 28 (55)
Coded Require submission of information about the new study 22 (43) 48 (94)
Require submission of documentation of review from
external researcher’s IRB
18 (35) 36 (71)
Identified* Require submission of information about the new study 30 (59) 51 (100)
Require submission of documentation of review from
external researcher’s IRB
30 (59) 40 (75)
*Data missing from 2 respondents.
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To obtain biospecimens needed for genetic and genomic
studies, researchers may utilize collections within their
own institutions, acquire samples from biobanks at other
institutions, or work collaboratively with researchers at
other institutions who may have larger or more diverse
collections than their own [9,13,14]. However, little at-
tention has been paid to how IRBs across major biomed-
ical research institutions approach the review of studies
that use stored biospecimens, or their policies and pro-
cedures regarding inter-institutional sharing of biospeci-
mens. Our results shed light on these questions from
the perspective of IRB Administrative Directors at insti-
tutions associated with CTSAs.
First, much of the variability in ADs’ responses regard-
ing decisions about when to review studies that utilize
stored biospecimens was related to the level of identifia-
bility of those biospecimens. Generally, the more identi-
fiable biospecimens are, the more likely IRBs are to
require review of both a new protocol and the original
consent form used when the biospecimens were col-
lected from donors. All IRBs reported requiring an initial
review of studies using identifiable samples. Conversely,
there was more variability in responses for anonymized
biospecimens. ADs reported reviewing studies less fre-
quently when the specimens used in a new protocol
were anonymized. Although this is not surprising given
that anonymized specimens are not currently catego-
rized as human subjects research according to U.S. regu-
lations, most ADs (61%) in this study reported that an
initial review by their IRBs would be necessary even
when specimens are anonymized. This may be due to
the fact that many IRBs expect to make the determin-
ation whether protocols involve human subjects re-
search. However, a significant minority of ADs surveyed
said their IRBs do not require review for these kinds of
studies.
While there was more uniformity around decisions to
review studies using identifiable biospecimens, there wasa high degree of variation across respondents when
assessing the risk levels of those studies. About half of
the ADs surveyed said their IRBs would categorize re-
search using identifiable samples as “no more than min-
imal risk.” Alternatively, one third of ADs responded
that their IRBs would typically categorize research using
identifiable specimens as “greater than minimal risk.”
Further, a number of ADs were either unsure what level
of risk their IRBs would assign a study using identifiable
specimens, or thought their IRB would assess risk on a
case-by-case basis. The actual reasons for this variation
are unknown given that ADs were not presented with
scenarios depicting specific research projects that might
raise different levels of risks. We therefore do not know
what types of studies or risks ADs had in mind when
responding. Nevertheless, these data do provide us with
an important baseline to compare how identifiability
may influence an IRB’s categorization of risk for studies
proposing to use stored biospecimens.
Unclear policies or inconsistent attitudes regarding
risk assessment may hinder a researcher’s ability to an-
ticipate and address the human subject protections
needed when designing a research protocol. In addition,
it may be more difficult for investigators to collaborate
across institutions with divergent policies or practices
regarding review of protocols, or regarding the assess-
ment of risks posed by studies that utilize biospecimens,
if those policies create barriers to developing a cohesive
protocol across sites. It could be challenging, for ex-
ample, to develop a multi-site collaboration if each insti-
tution’s IRB has different expectations regarding the
need for obtaining new consent from donors about the
new proposed use(s).
Second, it appears that IRBs differ in their approaches
to data management when a new protocol is deemed to
fall outside the scope of the original consent form used
when biospecimens were collected. While all ADs indi-
cated that their IRBs would either allow or encourage
seeking new consent from donors, there was greater
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ymization of specimens and the applicability of a waiver
of informed consent. This variation could present a bar-
rier to collaboration if, for example, an IRB at one pro-
ject site would allow specimens to be de-identified and
re-used without obtaining new consent from the donors
while another would require donors to give consent for
each new use. It should be noted here that the anonymiza-
tion and re-use, without new consent, of existing speci-
mens is a matter of some controversy among bioethicists
concerned specifically with human research protections.
While some argue persuasively that biospecimen anon-
ymization reduces risks to levels so low that such studies
would not even qualify for regulatory protection under
the current regulatory framework (and that re-use of spec-
imens is a way to maximize the principle of beneficence),
others raise legitimate concerns about whether such a
practice may violate the expectations of the original do-
nors and thereby create a dignitary harm [2,6,15].
Lastly, we found variation in IRB practices regarding
the sharing of biospecimens with researchers at outside
institutions. When researchers wish merely to share
biospecimens across institutions but not participate in
the new uses of those specimens once they are shared,
most ADs indicated that their IRBs would not need to
review information regarding the study proposals or IRB
approvals from the outside institutions when biospeci-
mens are anonymized or coded. However, if a researcher
wanted to share identified biospecimens, we saw a
higher level of variation across IRBs. A slight majority
would want information regarding the proposal and
documentation of review from the external researcher’s
IRB.
By contrast, when biospecimen sharing included par-
ticipation of the original researchers who collected the
specimens in the new research project, most ADs re-
ported their IRBs’ expectations to receive information
about the protocol and to review documentation from
the external researcher’s IRB. When the proposed study
involves collaboration across institutions, and proposes
to use anonymized or coded specimens, about half of
ADs also indicated a need to review protocol materials.
While this variation may reflect differing practices re-
garding the review of studies using coded or anonymized
specimens more generally, our findings indicate that
IRBs distinguish between simple biospecimen sharing
and actual collaborations between institutions that in-
volve the uses of stored specimens. If this is the case,
differing policies regarding the need to review studies in-
volving anonymized or coded specimens may be a chal-
lenge for collaborating researchers. For example, if one
institution requires review of an outside collaborator’s
protocol, but that collaborating institution does not re-
quire review for protocols using anonymized samples,researchers may find themselves in a “Catch-22”
scenario.
All of these issues may become increasingly problem-
atic if the U.S. Department of Health and Human Ser-
vices (DHHS) issues a regulation that would require
informed consent from donors (or biospecimen contrib-
utors) for any future uses of all specimens. Released in
2009, the Advance Notice of Proposed Rule Making
(ANPRM) proposes a brief, general consent for any fu-
ture uses of biospecimens, even if they are stripped of
identifiers [16-18]. Because of these proposed changes,
IRBs may start seeing more protocols proposing to use
stored biospecimens in anticipation of potential policy
changes. Even if the DHHS does not issue a new rule re-
quiring consent for the use of all specimens (including
those that are anonymized), an ongoing discussion about
the identifiability of DNA among geneticists, ethicists
and others has included calls for more consistent federal
policies regarding identifiability of DNA and human sub-
ject protections [19,20]. Our data further highlight the
need for national guidelines from bodies like the Office
for Human Research Protections (OHRP) that would
promote clear and interoperable IRB practices regarding
use of banked specimens.
It is also crucial to recognize that IRB differences in
approaches to biobanking research may reflect norma-
tive disagreements among researchers, participants, IRB
members, and bioethics scholars regarding the interpret-
ation of federal policies that govern human subjects re-
search. Therefore, while variation in the policies and
practices of IRBs may be seen as a barrier to biospeci-
mens sharing or collaborative research, it also could re-
flect meaningful normative differences about human
subjects protections supported by the inherent flexibility
in the regulations. It will be increasingly important to
consider how to balance the need to support IRBs’ ability
to interpret policies within their own institutional contexts
while reducing barriers to inter-institutional research.
While interoperability may not always be warranted or
even possible, a set of guiding principles to address these
concerns would nonetheless be valuable.
Limitations
This study has a number of limitations. First, our sample
consisted of IRB Administrative Directors from larger
research institutions associated with CTSAs, and may
not represent the practices of all IRBs, including institu-
tions with less research intensity or fewer resources.
More research with non-CTSA institutions would help
to better understand the practices of a wider range of
IRBs. Second, the survey itself did not capture qualitative
responses from ADs, limiting our insight into why par-
ticular approaches are taken by their IRB or how those
practices evolved. We did, however, conduct a subsequent
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from our sample [21].
Conclusion
Increasingly, translational genomic research requires
large numbers of biospecimens from diverse populations
and environments. Because this need for larger quan-
tities of biospecimens often exceeds the capacity of a
single institution, there is an increasing interest in the
collection, storage, and sharing of human biospecimens
and associated data across institutions. Our data indicate
that when reviewing proposed studies that utilize biospe-
cimens, IRBs at major academic health centers may take
differing approaches to protocol review, risk assessment,
and data sharing. These differing practices may result
from IRBs’ local interpretations of federal guidelines or
institutional practice, and are not inherently problematic
for the conduct of research. IRBs should be able to set
requirements that are consistent with federal standards
but also reflect institutional needs and legitimate differ-
ences in interpretation of legal requirements and ethical
norms. However, as the uses of stored biospecimens for
research increase, a lack of interoperable policies across
institutions may present barriers to inter-institutional
sharing of biospecimens. Divergent or unclear ap-
proaches to the review of studies utilizing biospecimens
may make navigating the IRB process more difficult or
potentially discourage collaboration between researchers
across institutions. More data are needed to determine
whether differing IRB policies are in fact making collab-
orative genetic research more difficult for researchers.
Our data do, however, indicate that reducing variability
in IRB approaches could improve the ability to conduct
genetic research using biobanked biospecimens within
and across academic health centers.
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